Page last updated: 2024-11-10

fg 9041

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FG 9041: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3899541
CHEMBL ID155265
CHEBI ID93492
SCHEMBL ID594575
SCHEMBL ID8128055
MeSH IDM0159031

Synonyms (79)

Synonym
AKOS000448016
fg 9041
c8h4n4o6
HMS3266C03
OPREA1_127694
BRD-K85266041-304-01-7
BRD-K64400208-001-01-8
HMS2599K21
AE-641/00586054
EU-0100345
dnqx, >=98% (tlc)
smr000230466
MLS000705107
6,7-dinitro-2,3-quinoxalinediol
NCGC00024490-01
lopac-d-0540
NCGC00015319-01
tocris-0189
BPBIO1_001176
BIOMOL-NT_000182
dnqx
2,3-quinoxalinedione, 1,4-dihydro-6,7-dinitro-
DB03759
6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione
fg-9041
1FTL
LOPAC0_000345
NCGC00024490-04
NCGC00024490-03
NCGC00024490-02
NCGC00015319-03
D 0540
NCGC00015319-06
CHEMBL155265
2379-57-9
AKOS005066561
HMS3261E11
CCG-204440
NCGC00015319-04
NCGC00015319-02
NCGC00015319-05
62t278s1mx ,
unii-62t278s1mx
6,7-dinitroquinoxaline-2,3-dione (dnqx)
LP00345
6,7-dinitroquinoxaline-2,3(1h,4h)-dione
FT-0620868
SCHEMBL594575
SCHEMBL8128055
NCGC00261030-01
tox21_500345
6,7-dinitro-1,4-dihydro-quinoxaline-2,3-dione
STL431184
HB0261
AC-33199
mfcd00069257
DTXSID60178476
HY-15067
sr-01000313889
SR-01000313889-1
CHEBI:93492
CS-5935
J-015214
SR-01000075442-3
sr-01000075442
SR-01000075442-1
STL507389
6,7-dinitroquinoxaline-2,3-diol
HMS3675A15
HMS3411A15
BRD-K64400208-001-02-6
A13882
SDCCGSBI-0050333.P002
BCP34647
fg 9041;fg9041;fg-9041
NCGC00015319-13
AS-55799
6,7-dinitro-1,2,3,4-tetrahydroquinoxaline-2,3-dione
2,3-quinoxalinedione,1,4-dihydro-6,7-dinitro-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
") were also resistant to the toxic effects of quisqualic acid, indicating the possible involvement of NMDA receptors in quisqualic acid toxicity."( Quisqualic acid-induced neurotoxicity is protected by NMDA and non-NMDA receptor antagonists.
Pai, KS; Ravindranath, V, 1992
)
0.28
" Using a variation of this approach, and measuring the acute and delayed toxic effects of kainate (KA) in terms of lactate dehydrogenase release, we have shown that guanine nucleotides behave as effective neuroprotecting agents."( Guanine nucleotides protect against kainate toxicity in an ex vivo chick retinal preparation.
Barat, A; Burgos, JS; Ramírez, G; Souza, DO, 1998
)
0.3
" DNQX toxic effect is neuron-specific since cultured hippocampal glial cells are unaffected."( DNQX-induced toxicity in cultured rat hippocampal neurons: an apparent AMPA receptor-independent effect?
Guiramand, J; Martin, A; Récasens, M, 2003
)
0.32
" DNQX (10 microM), an AMPA/kainate receptor antagonist, partly attenuated the toxic effects of QA, whereas LY 367 385 (100 microM), a selective mGluR1a antagonist, completely reversed the above effect."( Effects of estrone on quisqualate-induced toxicity in primary cultures of rat cortical neurons.
Kajta, M; Kubera, M; Lasoń, W; Marszał, M, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves obtained in oocytes were bell shaped, with a negative slope for high concentrations of QA."( Reduction of desensitization of a glutamate ionotropic receptor by antagonists.
Audinat, E; Crepel, F; Geoffroy, M; Hamon, B; Kado, RT; Lambolez, B; Rossier, J, 1991
)
0.28
" Bath-application of kainate, quisqualate and L-glutamate elicited concentration-dependent membrane depolarizations in both cell types as demonstrated by dose-response curves."( Effects of glutamatergic agonists and antagonists on membrane potential and intracellular Na+ activity of leech glial and nerve cells.
Dörner, R; Schlue, WR; Zens, M, 1994
)
0.29
" A dose-response effect was observed."( Behavioural motor effects of MK-801 and DNQX parenteral administration in adult cats: dose-response analysis. Modulatory role of dopaminergic D1 and D2 antagonists on MK-801 induced motor behaviours.
Gonzalez, M; Infante, C; Motles, E, 2000
)
0.31
"Systemic or regional administration of the non-competitive NMDA antagonist dizocilpine into the VTA significantly increased the rate of heroin SA and shifted the heroin dose-response curve to the right."( Blockade of ionotropic glutamatergic transmission in the ventral tegmental area reduces heroin reinforcement in rat.
Stein, EA; Xi, ZX, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinoxaline derivativeAny naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (58)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency89.12510.003245.467312,589.2998AID2517
thioredoxin reductaseRattus norvegicus (Norway rat)Potency4.24210.100020.879379.4328AID588453; AID588456
Microtubule-associated protein tauHomo sapiens (human)Potency1.97970.180013.557439.8107AID1460
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
glucocerebrosidaseHomo sapiens (human)Potency12.05410.01268.156944.6684AID2101
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02990.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency3.54810.540617.639296.1227AID2364; AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency56.23410.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency6.51310.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency22.38720.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency10.26630.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency0.03160.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Glycoprotein hormones alpha chainHomo sapiens (human)Potency0.31624.46688.344810.0000AID624291
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency47.39351.995325.532750.1187AID624287; AID624288
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, GLUTAMATE RECEPTOR SUBUNIT 2Rattus norvegicus (Norway rat)IC50 (µMol)0.99800.82105.439714.5000AID977608
Chain A, Glutamate Receptor Subunit 2Rattus norvegicus (Norway rat)IC50 (µMol)0.99800.82105.439714.5000AID977608
Chain B, Glutamate Receptor Subunit 2Rattus norvegicus (Norway rat)IC50 (µMol)0.99800.82105.439714.5000AID977608
fatty acid synthaseHomo sapiens (human)IC50 (µMol)7.75500.16605.647218.2000AID624326; AID624327
Glutamate receptor 1Rattus norvegicus (Norway rat)Ki0.36000.00000.41052.7800AID92651
Glutamate receptor 2Rattus norvegicus (Norway rat)Ki0.36000.00000.68536.3000AID92651
Glutamate receptor 3Rattus norvegicus (Norway rat)Ki0.36000.00000.71777.4000AID92651
Glutamate receptor 4Rattus norvegicus (Norway rat)Ki0.36000.00000.52773.5700AID92651
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)13.82500.00071.600310.0000AID143293; AID145260; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki0.39000.00030.86666.6900AID145326
Glutamate receptor 1Homo sapiens (human)IC50 (µMol)1.51000.01901.70836.5100AID1859112; AID1859129; AID1859130
Glutamate receptor 1Homo sapiens (human)Ki0.36000.01472.50379.2000AID92933
Glutamate receptor 2Homo sapiens (human)IC50 (µMol)1.51000.01901.64035.5000AID1859112; AID1859129; AID1859130
Glutamate receptor 2Homo sapiens (human)Ki0.36000.01681.27725.0000AID92933
Glutamate receptor 3Homo sapiens (human)IC50 (µMol)1.51000.01901.13424.8000AID1859112; AID1859129; AID1859130
Glutamate receptor 3Homo sapiens (human)Ki0.36000.02060.53222.2000AID92933
Glutamate receptor 4Homo sapiens (human)IC50 (µMol)1.51000.01901.22234.8000AID1859112; AID1859129; AID1859130
Glutamate receptor 4Homo sapiens (human)Ki0.36000.04001.23358.8500AID92933
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)13.82500.00071.630610.0000AID143293; AID145260; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki0.39000.00030.68056.6900AID145326
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)13.82500.00061.525710.0000AID143293; AID145260; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki0.39000.00030.70716.6900AID145326
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)13.82500.00071.747210.0000AID143293; AID145260; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki0.39000.00030.81966.6900AID145326
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)13.82500.00071.741110.0000AID143293; AID145260; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki0.39000.00030.70726.6900AID145326
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)13.82500.00071.741110.0000AID143293; AID145260; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Ki0.39000.00030.70726.6900AID145326
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)13.82500.00071.741110.0000AID143293; AID145260; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Ki0.39000.00030.70726.6900AID145326
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)Kb0.59000.59003.33007.0000AID163307
Glutamate receptor 2Rattus norvegicus (Norway rat)Kb0.59000.59003.17337.0000AID163307
Glutamate receptor 3Rattus norvegicus (Norway rat)Kb0.59000.59003.17787.0000AID163307
Glutamate receptor 4Rattus norvegicus (Norway rat)Kb0.59000.59003.28567.0000AID163307
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)Kb1.29001.29004.96339.0000AID91454
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Kb5.30000.00592.09697.0000AID143320
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)Kb1.29001.29004.96339.0000AID91454
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)Kb1.29001.29004.04509.0000AID91454
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Kb5.30000.00592.41137.0000AID143320
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Kb5.30000.00592.41137.0000AID143320
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Kb5.30000.00592.41137.0000AID143320
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)Kb1.29001.29004.96339.0000AID91454
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Kb5.30000.00592.41137.0000AID143320
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)Kb1.29001.29004.96339.0000AID91454
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Kb5.30000.00592.41137.0000AID143320
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Kb5.30000.00592.41137.0000AID143320
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (57)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of receptor recyclingGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synapse assemblyGlutamate receptor 1Homo sapiens (human)
long-term memoryGlutamate receptor 1Homo sapiens (human)
response to xenobiotic stimulusGlutamate receptor 1Homo sapiens (human)
response to lithium ionGlutamate receptor 1Homo sapiens (human)
positive regulation of gene expressionGlutamate receptor 1Homo sapiens (human)
neuronal action potentialGlutamate receptor 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 1Homo sapiens (human)
spinal cord developmentGlutamate receptor 1Homo sapiens (human)
cerebral cortex developmentGlutamate receptor 1Homo sapiens (human)
receptor internalizationGlutamate receptor 1Homo sapiens (human)
response to estradiolGlutamate receptor 1Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 1Homo sapiens (human)
response to cocaineGlutamate receptor 1Homo sapiens (human)
positive regulation of membrane potentialGlutamate receptor 1Homo sapiens (human)
response to arsenic-containing substanceGlutamate receptor 1Homo sapiens (human)
response to electrical stimulusGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 1Homo sapiens (human)
long-term synaptic depressionGlutamate receptor 1Homo sapiens (human)
response to fungicideGlutamate receptor 1Homo sapiens (human)
cellular response to amino acid stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to ammonium ionGlutamate receptor 1Homo sapiens (human)
cellular response to dsRNAGlutamate receptor 1Homo sapiens (human)
cellular response to peptide hormone stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to amine stimulusGlutamate receptor 1Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusGlutamate receptor 1Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 2Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 2Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 2Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor 2Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 3Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 3Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
protein homotetramerizationGlutamate receptor 3Homo sapiens (human)
protein heterotetramerizationGlutamate receptor 3Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 3Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 3Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 3Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 4Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processGlutamate receptor 4Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 4Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 4Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
amyloid-beta bindingGlutamate receptor 1Homo sapiens (human)
G-protein alpha-subunit bindingGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
protein bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
adenylate cyclase bindingGlutamate receptor 1Homo sapiens (human)
immunoglobulin bindingGlutamate receptor 1Homo sapiens (human)
protein kinase bindingGlutamate receptor 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 1Homo sapiens (human)
PDZ domain bindingGlutamate receptor 1Homo sapiens (human)
small GTPase bindingGlutamate receptor 1Homo sapiens (human)
myosin V bindingGlutamate receptor 1Homo sapiens (human)
G-protein beta-subunit bindingGlutamate receptor 1Homo sapiens (human)
beta-2 adrenergic receptor bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor bindingGlutamate receptor 1Homo sapiens (human)
identical protein bindingGlutamate receptor 1Homo sapiens (human)
protein kinase A bindingGlutamate receptor 1Homo sapiens (human)
scaffold protein bindingGlutamate receptor 1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 2Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
protein bindingGlutamate receptor 2Homo sapiens (human)
ligand-gated monoatomic cation channel activityGlutamate receptor 2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 3Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 3Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 3Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 4Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 4Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (42)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
cell-cell junctionGlutamate receptor 1Homo sapiens (human)
cell surfaceGlutamate receptor 1Homo sapiens (human)
ER to Golgi transport vesicle membraneGlutamate receptor 1Homo sapiens (human)
postsynaptic densityGlutamate receptor 1Homo sapiens (human)
dendriteGlutamate receptor 1Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 1Homo sapiens (human)
synaptic vesicle membraneGlutamate receptor 1Homo sapiens (human)
neuromuscular junctionGlutamate receptor 1Homo sapiens (human)
early endosome membraneGlutamate receptor 1Homo sapiens (human)
dendritic spine membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell body membraneGlutamate receptor 1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell bodyGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
dendritic shaftGlutamate receptor 1Homo sapiens (human)
axonal spineGlutamate receptor 1Homo sapiens (human)
neuron spineGlutamate receptor 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor 1Homo sapiens (human)
presynaptic active zone membraneGlutamate receptor 1Homo sapiens (human)
recycling endosomeGlutamate receptor 1Homo sapiens (human)
recycling endosome membraneGlutamate receptor 1Homo sapiens (human)
excitatory synapseGlutamate receptor 1Homo sapiens (human)
synaptic membraneGlutamate receptor 1Homo sapiens (human)
presynapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
glutamatergic synapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density, intracellular componentGlutamate receptor 1Homo sapiens (human)
perisynaptic spaceGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
external side of plasma membraneGlutamate receptor 2Homo sapiens (human)
postsynaptic densityGlutamate receptor 2Homo sapiens (human)
dendriteGlutamate receptor 2Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 2Homo sapiens (human)
asymmetric synapseGlutamate receptor 2Homo sapiens (human)
neuronal cell bodyGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
excitatory synapseGlutamate receptor 2Homo sapiens (human)
postsynapseGlutamate receptor 2Homo sapiens (human)
postsynaptic endocytic zoneGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic membraneGlutamate receptor 3Homo sapiens (human)
parallel fiber to Purkinje cell synapseGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 3Homo sapiens (human)
dendritic spineGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendriteGlutamate receptor 4Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 4Homo sapiens (human)
neuronal cell bodyGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
extracellular vesicleGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 4Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 4Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (63)

Assay IDTitleYearJournalArticle
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2000Neuron, Oct, Volume: 28, Issue:1
Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core.
AID1811Experimentally measured binding affinity data derived from PDB2000Neuron, Oct, Volume: 28, Issue:1
Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID92191The compound was tested for the % displacement of [3H]AMPA binding to Ionotropic glutamate receptor AMPA in rat brain membranes at a concentration of 100 uM1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Design and synthesis of enantiomers of 3,5-dinitro-o-tyrosine: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonists.
AID145260In vitro inhibition of [3H]glycine at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID91454Apparent dissociation constant for [3H]kainate from Ionotropic glutamate receptor kainate of rat cortical slices1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID496837Inhibition of NMDA receptor glycine site from rat cortical membrane2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID92352Binding affinity was determined against ionotropic glutamate receptor AMPA in rat brain synaptic membranes using [3H]AMPA as radioligand1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID1859130Displacement of [3H]kainic acid from AMPA receptor (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID1859129Displacement of [3H]CNQX from AMPA receptor (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID92933Binding affinity against Ionotropic glutamate receptor AMPA using [3H]AMPA as a radioligand1995Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25
(3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID93568Inhibition of [3H]- Kainate binding to Ionotropic glutamate receptor kainate in brain homogenates.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor agonists and antagonists.
AID1859112Displacement of [3H]AMPA from AMPA receptor (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID180108Inhibition of stimulation of NE release by 100 uM of AMPA1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Structure--activity studies for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptors: acidic hydroxyphenylalanines.
AID92045Inhibition of Ionotropic glutamate receptor AMPA binding to human hippocampal homogenates at concentration of 5-7 uM1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
6-(4-pyridinyl)-1H-1,2,3-triazolo[4,5-d]-pyrimidin-4(5H)-one: a structurally novel competitive AMPA receptor antagonist.
AID143322Binding affinity towards glycine site on the NMDA receptor was determined1995Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25
(3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist.
AID92515Displacement of [3H]- AMPA from Ionotropic glutamate receptor of rat brain1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor agonists and antagonists.
AID496836Inhibition of NMDA receptor glutamate site from rat cortical membrane2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID31606Binding affinity against AMPA receptor in rat brain membrane using [3H]-AMPA as radioligand1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor.
AID93719Inhibition of specific binding of [3H]kainate to Ionotropic glutamate receptor kainate in rat brain membranes1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Structure--activity studies for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptors: acidic hydroxyphenylalanines.
AID163307Apparent dissociation constant of [3H]AMPA from Quisqualate receptor of rat cortical slices1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID496835Displacement of [3H]kainate from kainate receptor in rat cortical membrane2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID143320Apparent dissociation constant of [3H]glycine from N-methyl-D-aspartate glutamate receptor of rat cortical slices1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID92497Inhibition of specific binding of [3H]AMPA to Ionotropic glutamate receptor AMPA in rat brain membranes1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Structure--activity studies for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptors: acidic hydroxyphenylalanines.
AID496834Displacement of [3H]AMPA from AMPA receptor in rat cortical membrane2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID92041Percent control measured by evaluating the inhibition of 3 nM [125I]PhTX-343-lysine binding to glutamate receptors in rat cortical membranes1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and binding of [125I2]philanthotoxin-343, [125I2]philanthotoxin-343-lysine, and [125I2]philanthotoxin-343-arginine to rat brain membranes.
AID145326Compound was tested for its ability to displace [3H]glycine from glycine site on the N-methyl-D-aspartate glutamate receptor1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones.
AID143293Inhibition of [3H]glycine binding to N-methyl-D-aspartate glutamate receptor of rat cortical membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID92651Compound was tested for its ability to displace [3H]-AMPA from AMPA receptor1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones.
AID93727Displacement of [3H]- Kainate from Ionotropic glutamate receptor kainate of rat brain homogenates.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor agonists and antagonists.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (807)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (1.73)18.7374
1990's374 (46.34)18.2507
2000's272 (33.71)29.6817
2010's138 (17.10)24.3611
2020's9 (1.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.55 (24.57)
Research Supply Index6.70 (2.92)
Research Growth Index6.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (0.62%)6.00%
Case Studies1 (0.12%)4.05%
Observational0 (0.00%)0.25%
Other806 (99.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]